Breast Cancer Histopathology Employs Infrared Spectroscopic Imaging
|
By LabMedica International staff writers Posted on 19 Apr 2021 |

Image: Spatial and quantitative comparison of high-definition (HD) and standard definition (SD) classification performance using the 6-class model (Photo courtesy of University of Illinois at Urbana−Champaign)
Digital analysis of cancer specimens using spectroscopic imaging coupled to machine learning is an emerging area that links spatially localized spectral signatures to tissue structure and disease. Breast histopathology, as an example of the broad relevance of these techniques, is critically important for clinical diagnoses.
Current histologic characterization is morphology-based; thin tissue sections are stained, and cells are visually recognized by a pathologist using an optical microscope. However, the basis of the disease is well known to be molecular. Molecular analysis for pathology is complicated by the spatial diversity of cells and acellular materials, necessitating an analytical technique that involves imaging.
Bioengineers at the University of Illinois at Urbana−Champaign (Urbana, IL, USA) and their colleagues examined the role of spatial-spectral tradeoffs in infrared spectroscopic imaging configurations for probing tumors and the associated microenvironment profiles at different levels of model complexity. The imaged breast tissue using standard and high-definition Fourier Transform Infrared (FT-IR) imaging and systematically examine the localization, spectral origins, and utility of data for classification.
The team obtained formalin-fixed, paraffin-embedded serial breast tissue microarrays (TMA) sections. The array consisted of a total of 101 cores of 1 mm diameter from 47 patients. Two sections were stained with hematoxylin and eosin (H&E) and other immunohistochemical markers and imaged with a light microscope. High-definition (HD) FT-IR imaging was conducted using the Agilent Stingray imaging system (Santa Clara, CA, USA) which is comprised of a 680-IR spectrometer coupled to a 620-IR imaging microscope with 0.62 numerical aperture, 25×objective.
The scientists provided a systematic comparison in the use of HD and SD FT-IR imaging data for breast pathology in their study. While the increased spatial localization of spectral signals in HD imaging may have been expected to provide a confounding influence, the study demonstrated that accuracy can be high, and there is significant potential in this sampling mode offering higher sensitivity. The team stated that IR imaging can not only provide the recognition capability of molecular data but can also balance that with an increased quality of morphologic data.
Rohit Bhargava, PhD, bioengineering professor and senior author of the study, said, “As technology expands and provides more capabilities with new features, it becomes more difficult to choose the optimal technology from the many options available. This study provides a nice comparison and guidelines to design a more useful and practical technology.” The study was originally published on February 27, 2021 in the journal Clinical Spectroscopy.
Related Links:
University of Illinois at Urbana−Champaign
Current histologic characterization is morphology-based; thin tissue sections are stained, and cells are visually recognized by a pathologist using an optical microscope. However, the basis of the disease is well known to be molecular. Molecular analysis for pathology is complicated by the spatial diversity of cells and acellular materials, necessitating an analytical technique that involves imaging.
Bioengineers at the University of Illinois at Urbana−Champaign (Urbana, IL, USA) and their colleagues examined the role of spatial-spectral tradeoffs in infrared spectroscopic imaging configurations for probing tumors and the associated microenvironment profiles at different levels of model complexity. The imaged breast tissue using standard and high-definition Fourier Transform Infrared (FT-IR) imaging and systematically examine the localization, spectral origins, and utility of data for classification.
The team obtained formalin-fixed, paraffin-embedded serial breast tissue microarrays (TMA) sections. The array consisted of a total of 101 cores of 1 mm diameter from 47 patients. Two sections were stained with hematoxylin and eosin (H&E) and other immunohistochemical markers and imaged with a light microscope. High-definition (HD) FT-IR imaging was conducted using the Agilent Stingray imaging system (Santa Clara, CA, USA) which is comprised of a 680-IR spectrometer coupled to a 620-IR imaging microscope with 0.62 numerical aperture, 25×objective.
The scientists provided a systematic comparison in the use of HD and SD FT-IR imaging data for breast pathology in their study. While the increased spatial localization of spectral signals in HD imaging may have been expected to provide a confounding influence, the study demonstrated that accuracy can be high, and there is significant potential in this sampling mode offering higher sensitivity. The team stated that IR imaging can not only provide the recognition capability of molecular data but can also balance that with an increased quality of morphologic data.
Rohit Bhargava, PhD, bioengineering professor and senior author of the study, said, “As technology expands and provides more capabilities with new features, it becomes more difficult to choose the optimal technology from the many options available. This study provides a nice comparison and guidelines to design a more useful and practical technology.” The study was originally published on February 27, 2021 in the journal Clinical Spectroscopy.
Related Links:
University of Illinois at Urbana−Champaign
Latest Pathology News
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
- CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
- Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Channels
Clinical Chemistry
view channel
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Global Survey Underscores Need to Standardize Bone Biomarker Testing
Bone and mineral metabolism biomarkers can complement dual-energy X-ray absorptiometry (DXA) by providing information on disease activity and treatment response. For more than 20 years, standardization... Read more
Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more
Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
Blood clots can rapidly become life‑threatening and affect approximately 10 million people worldwide each year. During time‑sensitive evaluations, clinicians use D‑dimer testing to help rule out deep vein... Read moreMolecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







